You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3β
|
|---|---|
| Published in |
Molecular Cancer Therapeutics, April 2009
|
| DOI | 10.1158/1535-7163.mct-08-0712 |
| Pubmed ID | |
| Authors |
Joel T. Adler, Mackenzie Cook, Yinggang Luo, Susan C. Pitt, Jianhua Ju, Wenli Li, Ben Shen, Muthusamy Kunnimalaiyaan, Herbert Chen |
| Abstract |
Medullary thyroid cancer (MTC) is a relatively uncommon neuroendocrine tumor that arises from the calcitonin-secreting parafollicular cells of the thyroid gland. Unfortunately, MTC frequently metastasizes, precluding curative surgical resection and causing significant morbidity. Thus, there is an urgent need for new treatment modalities. Tautomycin and tautomycetin are antifungal antibiotics isolated from Streptomyces spiroverticillatus and Streptomyces griseochromogens, respectively. Glycogen synthase kinase-3beta is a serine/threonine protein kinase that regulates multiple cellular processes and is important in various cancers, including MTC. Treatment with tautomycin and tautomycetin decreased neuroendocrine markers, suppressed hormonal secretion, and inhibited growth through apoptosis in MTC cells. Importantly, we describe a novel action of these compounds: inhibition of glycogen synthase kinase-3beta. |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 3% |
| Unknown | 28 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 24% |
| Student > Ph. D. Student | 4 | 14% |
| Student > Bachelor | 3 | 10% |
| Student > Doctoral Student | 2 | 7% |
| Lecturer | 2 | 7% |
| Other | 6 | 21% |
| Unknown | 5 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 7 | 24% |
| Biochemistry, Genetics and Molecular Biology | 6 | 21% |
| Medicine and Dentistry | 5 | 17% |
| Chemistry | 3 | 10% |
| Unknown | 8 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 May 2022.
All research outputs
#6,377,613
of 22,660,862 outputs
Outputs from Molecular Cancer Therapeutics
#1,418
of 3,858 outputs
Outputs of similar age
#24,211
of 78,648 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#21
of 45 outputs
Altmetric has tracked 22,660,862 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 3,858 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has gotten more attention than average, scoring higher than 61% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 78,648 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 45 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.